The International Initiative on Thrombosis and Cancer (ITAC), the international section of the Groupe Francophone Thrombose et Cancer (GFTC), presents this educational platform for specialist physicians and nurses involved in the care of patients with cancer who are at risk of venous thromboembolism (VTE) or with established VTE, including central venous catheter-related thrombosis (CRT).
Friday, May 31, 2019
We are happy to inform you that we are going to be in Melbourne, Australia, July 6-10, 2019, for the 27th Congress of the International Society on Thrombosis and Hemostasis.
ITAC has been assigned the booth #1114 in the exhibition area.
Join us there!
Wednesday, March 20, 2019
Plan to attend the ISTH 2019 Congress in Melbourne, Australia from 6-10 July 2019. This 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) is the premier global event for medical professionals and experts in bleeding and clotting disorders.
ISTH 2019 will bring together thousands of the world's leading specialists in thrombosis, hemostasis and vascular biology to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care.
Learn more and register at www.isth2019.org.
Sunday, July 9, 2017
ITAC-CME is pleased to report the success of our scientific session “Adopting New VTE and Cancer Guidelines: Is Clinical Practice Improving?” at the 2017 International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin on July 9. Attendance at the session far exceeded our expectations; we initially planned for 350 audience members, but had to double the size of the room – and even then there was a large contingent of attendees who watched the session by video in an overflow room! Thank you to everyone who attended and for your interest in the actions we’re taking to improve prophylaxis and treatment of VTE in patients with cancer. If you missed the session, view the presentation now.
Tuesday, March 7, 2017
Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with venous thromboembolism (VTE) can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis.
Full citation: Farge D, Bounameaux H, Bauersachs RM, Brenner B. Women, thrombosis, and cancer: A gender-specific analysis. Thromb Res 2017 Mar;151(Suppl 1):S21-9.
Wednesday, October 5, 2016
ITAC-CME announced the publication of its updated 2016 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer in The Lancet Oncology. Endorsed by the International Society on Thrombosis and Haemostasis (ISTH), the guidelines include recommendations for treatment and prophylaxis for both in-hospital and outpatient cancer-associated VTE in specific cancer patient subgroups, and provides first-ever guidance for the appropriate use of the direct oral anticoagulants in the treatment of VTE in cancer patients.
Full citation: Farge-Bancel D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. 2016 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer. Lancet Oncol 2016 Oct;17(10):e452-e466.